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ABSTRACT
Introduction The Community Ageing Research 75+ 
(CARE75+) study is a longitudinal cohort study collecting 
extensive health and social data, with a focus on frailty, 
independence and quality of life in older age. CARE75+ 
was the first international experimental frailty research 
cohort designed using trial within cohorts (TwiCs) 
methodology, aligning epidemiological research with 
clinical trial evaluation of interventions to improve 
the health and well- being of older people. CARE75+ 
REMOTE is an extension of CARE75+ using a remote 
model that does not require face- to- face interactions for 
data collection in the current circumstances of a global 
pandemic and will provide an efficient, sustainable data 
collection model.
Methods and analysis Prospective cohort study using 
TwiCs. One thousand community- dwelling older people 
(≥75 years) will be recruited from UK general practices by 
telephone. Exclusions include: nursing home/care home 
residents; those with an estimated life expectancy of 3 
months or less; and people receiving palliative care.
Data collection Assessments will be conducted by 
telephone, web- submission or postal questionnaire: 
baseline, 6 months, 12 months, 18 months, 24 months, 
30 months and 36 months. Measures include activities 
of daily living, mood, health- related quality of life, 
comorbidities, medications, frailty, informal care, 
healthcare and social care service use. Consent will be 
sought for data linkage and invitations to additional studies 
(sub- studies).
Ethics and dissemination CARE75+ was approved by 
the National Research Ethics Service (NRES) Committee 
Yorkshire and the Humber—Bradford Leeds 10 October 
2014 (14/YH/1120). CARE75+ REMOTE (amendment 13) 
was approved on the 18th November 2020. Consent is 
sought if an individual is willing to participate and has 
capacity to provide informed consent. Consultee assent 
is sought if an individual lacks capacity. Results will 
be disseminated in peer- reviewed scientific journals 
and conferences. Results will be summarised and 
disseminated to study participants via newsletters, local 
engagement events and on a bespoke website.
Trial registration number ISRCTN16588124.
INTRODUCTION
Global demographic projections indicate 
that there will be two billion people aged 
over 65 worldwide by 2050.1 With increasing 
life expectancy, there are projected to be 
more older people living with multiple health 
conditions.2 Frailty is an especially problem-
atic expression of population ageing, with 
profound implications for the planning and 
delivery of health and social care services. 
Frailty is characterised by age- related decline 
Strengths and limitations of this study
 ► The Community Ageing Research 75+ (CARE75+) 
study is a prospective cohort study recruiting older 
people aged 75 years and over, designed using trial 
within cohorts (TwiCs) methods.
 ► Outcome measures were agreed following 
discussions with academic partners and lay 
representatives.
 ► CARE75+ REMOTE will continue to recruit under-
served populations including participants from the 
South Asian community and those with advanced 
frailty.
 ► Care home residents are not eligible for the study, 
aligned with the TwiCs design, meaning that findings 
cannot be generalised to non- community dwelling 
older people or those with very advanced frailty.
 ► CARE75+ REMOTE will provide important data 
during a time of national pandemic (COVID- 19) and 
will provide a highly efficient, sustainable model of 
data collection in the future.
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across multiple physiological systems and vulnerability 
to disproportionate changes in health after relatively 
minor health events, such as a minor infection or minor 
surgery.3 It is estimated that frailty affects around 12% of 
people aged≥50 years globally, rising to around one- third 
of those aged over 80 years.4 In the last 20 years, there has 
been a conceptualisation of frailty as an abnormal health 
state in relation to the ageing process, resulting in the 
development of robust models and tools to identify and 
severity grade frailty.5 6 Increasingly, frailty is considered 
a long- term condition requiring long- term strategies and 
interventions.7 However, the recruitment of older people 
into research, particularly those with frailty, remains 
challenging.8
The Community Ageing Research 75+ (CARE75+) 
study was established in 2014.9 The aim of the study was 
to establish a longitudinal cohort of older people to inves-
tigate ageing, frailty, disability and quality of life in older 
age. Additionally, the CARE75+ study aimed to provide a 
research recruitment platform for other research studies 
(sub- studies) to enable the development and evaluation 
of interventions to improve outcomes for people in later 
life.
By 2020, 1323 participants had been recruited into 
the CARE75+ cohort. Participants ranged in age from 75 
years to 98 years (at baseline assessment) and included 
people across the spectrum of health and frailty, from 
varied ethnic and socioeconomic backgrounds. Partici-
pants were recruited from a mixture of urban and rural 
locations across England including Bradford, Leeds, Hull, 
Scarborough, Newcastle, Durham, Doncaster, Oswestry, 
Stafford, Wolverhampton, Exeter and Plymouth.
To date, the study has provided a valuable data resource 
for research on topics pertinent to older people.10–14 The 
CARE75+ study has also provided a successful recruit-
ment platform for research with older people, with 
approximately 85% of participants providing consent to 
be contacted about additional studies (sub- studies). This 
has enabled stratified sampling and the identification of 
underserved populations,15 including for studies on the 
effect of ageing on skeletal muscle16; resourcefulness in 
later life and the impact of lockdown on the lives of older 
people during the COVID- 19 pandemic.17
CARE75+ REMOTE
In 2019, additional funding was secured for CARE75+ via 
the National Institute for Health Research Applied 
Research Collaboration, Yorkshire and Humber (NIHR 
ARCYH)18 and an updated CARE75+ assessment schedule 
was planned to reflect new research priorities, mainly 
structured around face- to- face data collection methods, 
alternating with telephone or web- based data collection 
at follow- up time points. Outcome measures were agreed 
following discussions with academic partners and lay 
representatives through a purposely established Patient 
and Public Involvement (PPI) Frailty Oversight Group 
(FOG).19 The updated CARE75+ assessment schedule was 
designed to provide the necessary data and recruitment 
platform for planned studies funded as part of the NIHR 
ARCYH (https://www. arc- yh. nihr. ac. uk/ what- we- do/ 
older- people). However, the advent of the COVID- 19 
pandemic has necessitated adaption of study procedures 
to recruit new participants without face- to- face interac-
tions. As a result, the CARE75+ REMOTE model has been 
developed. This model will enable key outcome measures 
to be captured that do not require face- face interactions. 
For a description of the different study pathways for the 
CARE75+ study, see table 1.
In addition to supporting ongoing recruitment during 
the current COVID- 19 pandemic, the CARE75+ REMOTE 
model will enhance sustainability of the cohort as a 
platform for applied epidemiology and novel research 
involving older people. It is also recognised that research 
during the COVID- 19 pandemic failed to meet the chal-
lenges of older people, even though this group was 
disproportionately affected by the pandemic in terms 
of restrictions on social contact and mortality.20 Imple-
menting remote cohort consent, data collection and 
follow- up methods in advance of a future pandemic will 
ensure that the ageing research community is better 
prepared for future research that meets the needs of this 
underserved population15 and is cost- effective.
AIM
The main aim of CARE75+ REMOTE is to use remote 
consent, assessment and follow- up methods to support 
epidemiological investigation of ageing, frailty, health 
and well- being and health and social care use in older 
age. CARE75+ REMOTE will also provide a recruitment 
platform for planned sub- studies within the ARC Older 
People’s programme (https://www. arc- yh. nihr. ac. uk/ 
what- we- do/ older- people) and to enable the develop-
ment and evaluation of future interventions to improve 
outcomes for older people.
OBJECTIVES
 ► To recruit and follow- up older people aged 75+ across 
a range of urban and rural areas using remote 
methods at 6 monthly intervals for 36 months.
 ► To support epidemiological analysis relating to 
healthy ageing and frailty in later life.
 ► To establish the necessary infrastructure for devel-
opment and evaluation of interventions to improve 
outcomes, using TWiCs methods.
PATIENT AND PUBLIC INVOLVEMENT
The PPI model of engagement, which underpins the 
CARE75+ study, is described in detail elsewhere.19 For 
CARE75+ REMOTE, we have worked with the FOG 
to enable researchers to test the CARE75+ REMOTE 
protocol, to ensure it is not overly burdensome and test 
the postal questionnaire, where multiple iterations were 
tested prior to an agreed final version.
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Table 1 CARE75+ study pathways
CARE75+ CARE75+ REMOTE CARE75+2
Recruitment start December 2014 May 2021 Anticipated start April 2022
Recruitment end March 2020 September 2024
Recruitment target 2500 across all CARE75+ study pathways by September 2024
Recruitment to date 1323 14 0
Study status No new recruitment on this pathway. 
Follow- ups in progress
On- going with recruitment and follow- 
ups underway
Not started. REC approval in 
place
Consent In person, at the participant’s home Telephone (audio- recorded) or postal In person, at the participant’s 
home
In person, at a general practice 
location
Assessment format In person, at the participant’s home, apart 
from at 6 months where there is the option 
of a modified protocol by telephone or 
web submission.
Postal questionnaire, web submission 
or by telephone
If there is deterioration in the 
participant’s health, hearing or vision, 
or cognition, during the course of the 
study, which makes the above formats 
problematic, face- to- face assessments 
will be undertaken if safe and feasible.
In person at baseline, 12 
months and 24 months
intermediate and final 
assessments (6, 18, 30 and 
36 months) will be conducted 
by telephone, postal or web 
submission
Option for in- person 
assessments to take place at a 
general practice location.
Assessment time points Baseline, 6, 12, 24, 48 months Baseline, 6, 12, 18, 24, 30, 36 months Baseline, 6, 12, 18, 24, 30, 36 
months
Outcome domains 




Health- related quality of life



















Feeling safe in your neighbourhood
Anxiety
Informal care





















Access to the internet
Feeling safe in your 
neighbourhood
Blood samples Yes (limited sites only) No Yes (limited sites only)
Notes Due to the impact of COVID- 19, face- to- 
face follow- up assessments moved to 
telephone assessments until June 2021 
when face- to- face visits were able to 
resume with specific safety measures in 
place, and depending on guidance by 
individual NHS trusts and the research 
capacity within individual Clinical 
Research Network organisations.
CARE75+ REMOTE and CARE75+2 study arms will run concurrently.
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DESIGN
A UK multisite, community- based cohort study designed 
using Trial within Cohorts (TWiCs) methods.21
Inclusion criteria
Community- dwelling older people aged≥75 years.
Exclusion criteria
People with an established life- limiting condition, life 
expectancy of 3 months or less and people in receipt of 
end of life palliative care services will be excluded. Care 
home and nursing residents and people living at home 
who are bedbound will be excluded. However, we will 
attempt to follow- up people who transition to a care 
home during the course of the study if feasible to do so.
Recruitment
We will work with general practices to identify and recruit 
participants from primary care patient lists. Following 
initial piloting of CARE75+ REMOTE with participants in 
Bradford, we will extend recruitment to other practices 
across England, using the skills and experience of staff 
within the NIHR Clinical Research Networks (CRN). 
Proposed CRN sites include: Thames Valley & South 
Midlands, North East and North Cumbria, South West 
Peninsula, West Midlands and Yorkshire & Humber. 
These regions provide geographic and socioeconomic 
diversity and contrasting urban/rural communities. See 
figure 1 for The CARE75+ REMOTE recruitment flow 
and assessment schedule.
Initial participant contact
Potential participants will be posted a study invitation 
pack containing a letter of invitation from the study 
team, a letter from their general practice and a brief 
user- friendly participant information leaflet to outline 
the study. The concise information sheet will include the 
CARE75+ CARE75+ REMOTE CARE75+2
CARE75+, Community Ageing Research 75+ ; GP, General Practice; NHS, National Health Service; REC, Research Ethics Committee.
Table 1 Continued
Figure 1 The Community Ageing Research 75+ (CARE75+) REMOTE study recruitment flow and assessment schedule.
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names of the CARE75+ REMOTE study lead and study 
manager, and the local researchers who will make the first 
telephone contact with the potential participant. Those 
not interested in participating in the study will be advised 
to contact their general practice to opt out of further 
contact, thus replicating the successful recruitment meth-
odology adopted in the first iteration of CARE75+.9
If potential participants do not opt out of being 
contacted, their contact details will be provided to the 
research team approximately 2 weeks later via a secure 
email system. These details will be uploaded onto a 
bespoke CARE75+ data application developed by Tiger-
Team ( www. tigerteam. co. uk). The researcher named 
on the brief information sheet will follow up with a tele-
phone call to enquire whether the information has been 
received and to discuss the study in more detail. If interest 
in participation is expressed, the researcher will post out 
comprehensive study information and arrange a time to 
phone the participant back. During the follow- up call, 
verbal informed consent will be sought if the potential 
participant wishes to proceed.
Monitoring numbers that opt out/do not consent
We will ask general practices to record the number 
of people who opt out of their contact details being 
forwarded to the research team. We will also monitor 
the number of people who do not opt out but: cannot be 
contacted by telephone; do not want to proceed (and the 
reasons if reported) or are unable to proceed (eg, due 
to severe hearing impairment or lacking capacity and are 
unable to identify a consultee to discuss participation).
Participant consent
A paper consent form will be posted to participants for 
completion and return to the study team. Alternatively, if 
the person is unable to get to the post box, the researcher 
will provide the option of consent by telephone, which 
will be audio recorded using encrypted devices with audio 
files stored securely. A transcript of the recording will be 
sent to the participant if requested. Participant consent 
will include twelve 12 mandatory items and 6 optional 
items (table 2).
Assessments
The CARE75+ REMOTE model includes demographic 
information and validated instruments for assessments 
of frailty, mood, health- related quality of life, indepen-
dence, comorbidities, medications as well as health and 
social care use and support. CARE75+ REMOTE includes 
measures with the necessary validity, reliability and 
responsiveness for applied epidemiological investigation 
and as validated outcome measures for future embedded 
randomised controlled trials (RCT) of interventions to 
improve outcomes for those in later life.
CARE75+ REMOTE assessments
 ► Demographic data including personal and family 
information.
 ► Instrumental activities of daily living (Nottingham 
Extended Activities of Daily Living, NEADL).22 The 
NEADL includes questions on everyday activities in 
the domains of mobility, kitchen, domestic and leisure 
and is scored between 0 and 66, with higher scores 
indicating greater independence.
 ► Health- related quality of life, measured using the 
EuroQol Five Dimension Health Questionnaire (five- 
level version) EQ- 5D- 5L.23 The EQ- 5D- 5L dimensions 
are: mobility, self- care, usual activities, pain/discom-
fort and anxiety/depression. Each dimension has 
five levels of severity: no problems, slight problems, 
moderate problems, severe problems and extreme 
problems. The scores for each of the five dimensions 
are combined in a five- digit number, representing 
health status that can be converted into a utility index 
(0 for dead, 1 for perfect health and negative values 
for states worse than death).
 ► Short- Form- 12 item Health Survey, V.2 (SF12v2).24 
The 12 SF12v2 items are used to measure eight 
domains of health- related quality of life. The domains 
include physical functioning, role- physical; bodily 
pain; general health; vitality; social functioning; 
role emotional and mental health. The information 
obtained from the eight health domain scales is aggre-
gated to generate physical component summary and 
mental component summary scores as overall meas-
ures of physical and mental health- related quality of 
life.
 ► Depression, measured using the Personal Health 
Questionnaire Depression Scale (PHQ- 8).25 The 
PHQ- 8 case finding instrument assesses the severity 
of depression by asking eight questions to ascertain 
mood over the previous 2 weeks. There are four 
response options and the score is the sum of the eight 
items. A score of 10 or greater is considered major 
depression, 20 or more is severe major depression.
 ► Anxiety measured using the Generalised Anxiety 
Disorder 2- item (GAD- 2), a two- item case finding tool 
for generalised anxiety disorder, with four response 
options. The GAD- 2 score is obtained by summing the 
scores from each question.26 A score of three points is 
the cut point for identifying possible cases of anxiety.
 ► Cognition measured using the Mini Montreal 
Cognitive Assessment V.2.1, and administered by 
telephone.27
 ► Health and social care use
 – Community- based health and social services (in the 
last 3 months)
 – Usual method of transport to services
 – Community- based social care services, including 
respite care (in the last 3 months)
 – Hospital services (in the last 3 months) including 
accident and emergency; acute hospital admis-
sions; hospital outpatients (and transport to these 
services).
 ► Aids and adaptations
 – Type of aid, who provided it and the cost
 on N
ovem









pen: first published as 10.1136/bm






6 Brown L, et al. BMJ Open 2021;11:e048524. doi:10.1136/bmjopen-2020-048524
Open access 
 – Type of adaptation, who provided it and the cost.
 ► Informal support (provided by friends and family) 
and the approximate time (hours/min).
 ► Prescribed medication information (name, dose, 
frequency). This will be collected from the primary 
care electronic health record (EHR) or via data 
linkage.
 ► Frailty will be assessed via the electronic Frailty Index 
(eFI) score, obtained from primary care EHR data.28 
The eFI is based on the cumulative deficit model of 
frailty, including 36 variables recorded in the primary- 
care EHR as part of routine care. The eFI score is 
calculated as an equally weighted proportion of the 
number of deficits present in an individual relative 
Table 2 Mandatory and optional consent items for CARE75+ REMOTE
Mandatory consent items Optional consent items
(1) Have read the participant information sheet and been given a full verbal 
explanation of the study.
(1) A member of the study team to review records that may be 
held by social services about use of their services.
(2) Have been given enough time to think about the information. (2) Researchers asking if I am interested in taking part in future 
studies that have been approved by the CARE75+ oversight 
group and providing them with my contact details (name, 
address, phone number) and very limited information about me 
that will help them determine my suitability for future studies.
(3) Understand the reason for the research and what will happen if I take part. (3) The researchers accessing and using data about me, as 
described above, in the event of my death.
(4) Understand that I am free to withdraw from the research at any time. (4) The researchers informing my GP of my participation in the 
study.
(5) Understand that a member of the study team will review my medical 
records (primary care and hospital records), including my electronic health 
record.
(5) The researchers informing my GP if I am assessed as having 
an unmet health need.
(6) Understand that sections of my medical notes and data, including 
electronic health records, may be looked at by responsible individuals from 
the NHS Trust or regulatory authorities where it is relevant to my taking part in 
this research. I give permission for these individuals to access my records.
(6) If my capacity to make informed decisions should deteriorate 
during the course of this study I wish to remain a participant.
(7) Understand that all information about me will be kept strictly confidential 
and that information will be anonymous except in cases of safeguarding.
  
(8) Agree to my anonymous data being analysed by members of the 
research team and also by researcher teams outside of the team (this could 
include researchers from other universities) that have been approved by the 
CARE75+ data review committee.
(9) Agree to the researchers conducting over the phone assessments with 
me at baseline (my first assessment) and then for me to undertake an 
assessment at 6, 12, 18, 24, 30 and 36 months (options of telephone, postal 
questionnaire, or web submission).
(10) Understand that even if I withdraw from the above study, the data 
already collected about me will be used to analyse the results of the study, 
unless I specifically withdraw consent for this. I understand that my identity 
will remain anonymous.
(11) Agree to my details, including my name and address, and a copy of 
this consent form to be stored at Bradford Institute for Health Research at 
Bradford Royal Infirmary for the sole purpose of managing this study.
(12) Agree for my personal details (eg, NHS number, date of birth, postcode, 
sex and initials) to be used to link study data with current and future data 
sources. These include (but are not limited to) primary and secondary care 
electronic health record systems (eg, SystmOne, EMISWeb, Vision, Cerner 
EPR), health (eg, Hospital Episode Statistics, Biologics Register, Cancer 
Registry), social services (eg, Community Care Statistics), environmental 
(eg, Air Pollution), economic (eg, Work and Pensions Longitudinal Study, 
Indices of Multiple Deprivation) and research databases (eg, UK Biobank, 
ResearchOne, CPRD, Q Research, ELSA) (data linkage).
GP - General Practice
NHS - National Health Service
EPR - Electronic Patient Record
ELSA - English Longitudinal Study of Ageing
CPRD - Clinical Practice Research Datalink
CARE75+, Community Ageing Research 75+.
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to the total possible. The eFI enables identification 
of frailty categories (fit, mild frailty, moderate frailty, 
severe frailty). A cumulative deficit frailty index will 
also be operationalised using variables collected as 
part of the assessment schedule.
 ► Information on comorbidities will be collected via the 
primary care EHR or via data linkage.
Assessment schedule
Participants will be assessed at baseline with follow- up 
assessments at 6, 12, 18, 24, 30 and 36 months. The base-
line assessment will be conducted by telephone to capture 
demographic and family data and familiarise participants 
with the assessment questions. Follow- up assessments 
will be conducted by telephone, web submission or by a 
postal questionnaire, depending on participant prefer-
ence. A phone call will be made a couple of weeks prior 
to each assessment time point to ensure that the person 
is happy to proceed and identify their chosen method of 
assessment.
The assessment schedule for CARE75+ has been care-
fully designed to accelerate the frailty translational 
research pathway by aligning epidemiological investiga-
tion with the typical follow- up schedule for feasibility and 
definitive trials of interventions.
Face-to-face follow-up for some participants
We anticipate that some participants may have health or 
cognitive deterioration over their time in the study to an 
extent that they may struggle with the remote methods 
(telephone, postal or web submission) of assessments. 
For those participants, we will conduct follow- up assess-
ments in person, in their homes, if feasible and safe to 
do so.
Sample size
As of 2020, 1323 participants have consented to 
CARE75+. The aim is to recruit a further 1200 partici-
pants to achieve an approximate sample size of 2500 by 
September 2024. This will include participants recruited 
for CARE75+ REMOTE and for the planned full assess-
ment schedule for CARE75+2. The latter will be imple-
mented at some sites when face- face- face assessments can 
be resumed and sites have the necessary capacity.
This proposed sample size will provide a comprehensive 
dataset for applied epidemiological research, health and 
socioeconomic modelling and a recruitment platform 
for additional studies (substudies), including qualitative 
studies as well as RCTs using TwiCs methods.21 Therefore, 
the recruitment target is based on appropriate sample 
size calculations for pilot RCTs of interventions to inform 
the design of future definitive RCTs alongside applied 
epidemiological investigation of modifiable components 
of frailty. Previous observational studies involving older 
people with frailty have identified that between 600 and 
1000 participants are required for reliable estimates of 
the main effects.29
Plans to promote participant retention and complete follow-up
We will seek broad and enduring consent for data linkage 
and use of collected data following withdrawal or death, 
aligned with Medical Research Council guidelines for 
maximising the use of cohort data.30 Newsletters will be 
posted to participants at least two times a year to provide 
study updates and encourage continued engagement. We 
will hold annual engagement events, where feasible to do 
so, and promote the study locally via site affiliated and 
local forums.
Data entry, coding, security and storage
The electronic data capture application is provided by 
TigerTeam ( www. tigerteam. co. uk). It will comprise two 
main components: a data collection application (DCA) 
and back office system (BOS) containing personal identi-
fiable information. The application will run on the Micro-
soft Windows platform using an encrypted embedded 
database to temporarily store data. The BOS database 
will be on a Microsoft SQL server hosted at Bradford 
Teaching Hospitals NHS Foundation Trust (BTHFT). 
Named researchers will have access to the individual 
details only while data collection takes place. A partici-
pant’s details will only be released to one researcher at a 
time via the BOS management system. Access to modules 
and functions of both the DCA and BOS will be governed 
by usernames, passwords and role- specific access permis-
sions, to maximise data security.
Remote site data (outside BTHFT) and the web- 
submission forms will be transferred to the BIHR- 
CARE75+ database via the web application  auecr. 
bradfordhospitals. nhs. uk hosted on the web server bhts- 
bihrweb. The site will be protected by Secure Sockets 
Layer (SSL) certificates, to encrypt the transfer of data 
over the internet. Access to the web application on the 
server will be restricted and protected by the Threat 
Management Gateway software and SSL certificates. 
Remote site administrators and researchers will only have 
access to their local participants.
The chief investigator, project manager, database 
manager and core team members from CARE75+ based 
at BTHFT with Super Administrator roles will have access 
to all data, at all levels for administration and governance 
purposes. Local teams will be limited to access data of 
their participants only.
Researchers will have a maximum of three participants 
available on portable devices (laptops) at any one time. 
Statisticians and other members of the CARE75+ research 
team will only have access to pseudo anonymised that is, 
those with unique identifiers for use in data linkage or 
anonymous data. Individual participants will be limited to 
access to a blank follow- up questionnaire to complete and 
submit if undertaking web submission.
Data quality
Data quality will be enhanced by integral features of the 
data capture software, which will identify missing data and 
outlying values in real time. The software will automatically 
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calculate the total scores for composite assessments. This 
will increase research efficiency and research data quality 
by reducing resource required for data cleansing, coding 
for analysis and reduce input errors.
Statistical methods
We will use a range of appropriate statistical methods to 
investigate a broad range of research questions focusing 
on frailty, coexisting physical and mental health prob-
lems and independence in later life, including descrip-
tive epidemiology, prognostic modelling methods, causal 
epidemiology, transition and trajectory modelling. We 
will investigate health and social care resource use for 
people with frailty, multimorbidity and disability using 
economic modelling methods. Submission of detailed 
statistical analysis plans will be required as part of the 
data application process for researchers to obtain access 
to CARE75+ REMOTE data.
Missing data
Methods for dealing with missing data will depend on the 
amount of missing data and patterns of missingness for 
individual variables as part of individual analyses. We will 
undertake sensitivity analysis to investigate the impact of 
missing data and we will explore the use of appropriate 
imputation methods.
Ethics and dissemination
CARE75+ REMOTE is an observational study with low risk 
to participants. Cohort governance will be provided by 
the NIHR ARCYH (https://www. arc- yh. nihr. ac. uk/ what- 
we- do/ older- people) Operational Group comprising of 
theme leads, theme manager, project managers and coap-
plicants. The original CARE75+ protocol was approved by 
the National Research Ethics Service (NRES) Committee 
Yorkshire and the Humber—Bradford Leeds, October 
2014 (14/YH/1120). The CARE75+ REMOTE protocol 
(amendment number 13) was approved on 18 November 
2020.
Data sharing and data access
The protocol and participant- level dataset will be 
made available to not- for- profit investigators. Enqui-
ries will be made to the CARE75+ chief investigator or 
CARE75+ manager. Data request forms are available at 
https://www. bradfordresearch. nhs. uk/ care75/ data- 
request/. Requests will be reviewed by the CARE75+ data 
review committee, which comprises the study lead, study 
manager, academics within the Academic Unit for Ageing 
and Stroke Research, a PPI lay representative and a stat-
istician. For studies that request contact details for access 
to participants, they will first be invited to present their 
proposal to the established FOG.19 This is to ensure that 
the study is an appropriate use of the CARE75+ resource, 
being mindful that too many requests may be detrimental 
to the study overall if participants have multiple requests 
for their time or requests to participate in studies not rele-
vant to people in later life.
Bradford Teaching Hospitals NHS Foundation Trust 
is the data controller for CARE75+. Data will be made 
available to external researchers in accordance with 
CARE75+ data sharing protocols following review, 
completion of a data request form and completion of a 
data sharing agreement between BTHFT and the recip-
ient university or organisation.
Dissemination policy
Study results will be disseminated in peer- reviewed 
scientific journals and submitted to local, national and 
international scientific conferences. Key results will be 
summarised and disseminated to study participants via 
newsletters, local older people’s publication (eg, Voice 
magazine, Age UK) and local engagement events. Links 
to publications will be shared on the CARE75+ website 
(https://www. bradfordresearch. nhs. uk/ care75/) and 
the ARC Yorkshire and Humber website (https://
www. arc- yh. nihr. ac. uk/ home). Research outputs using 
CARE75+ study data or including CARE75+ participants 
will be required to acknowledge the data source and 
funder.
We will use the cross- ARC network and additional imple-
mentation expertise within ARC for https://www. arc- yh. 
nihr. ac. uk/ to maximise impact of research outputs. We 
will share results with an established Research Imple-
mentation Advisory Group that runs alongside the frailty 
research programme. The group has broad membership, 
with regional representation across NHS commissioner 
and provider organisations, adult social care, public 
health, voluntary sector and national policy representa-
tion. This implementation advisory group will act as a 
‘pull’ to facilitate getting frailty research findings into 
routine practice.
Ancillary and poststudy care
Some participants may be identified with unmet care 
needs and may wish to discuss these with the researcher. 
Where applicable, researchers will signpost participants 
to local statutory and voluntary organisations (eg, Age 
UK), or request a General Practice (GP) referral for 
social services assessment, so that appropriate plans can 
be made for ongoing care. Safeguarding issues identified 
during the assessment will be reported to the research 
project manager who will then take advice from the 
Adult Safeguarding Coordinator in the relevant local 
authorities.
DISCUSSION
CARE75+ REMOTE is designed using a remote model 
that does not require face- to- face interactions to support 
data collection in the extreme circumstances of a global 
pandemic, but to also provide a highly efficient, sustain-
able model of data collection. Remote data collection is 
less costly than face- to- face, an important consideration 
for publicly funded research, particularly in uncertain 
economic times. In line with the original CARE75+ study, 
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CARE75+REMOTE is designed using TwiCs methods21 to 
align applied epidemiological research with clinical trials 
of interventions, potentially accelerating the translational 
research pathway in the important area of improving 
health for older people living with multimorbidity and 
frailty. We plan to include a concise range of measure-
ments to capture important outcomes on mood, inde-
pendence, quality of life, health and social care use and 
frailty, including through use of the primary care EHR 
and routine data linkage.28
The new remote model, CARE75+ REMOTE, is not 
without challenges and we are mindful that a lack of 
face- to- face interactions may be less attractive to some 
participants than the original CARE75+ model. However, 
we have already used a remote model to collect data 
for CARE75+ follow ups, through web submission or 
telephone, and this has proven to be an effective form 
of data collection. We will monitor recruitment rates to 
ensure that we are still able to successfully recruit older 
people across the frailty spectrum, particularly those 
with advanced frailty, and compare the characteristics of 
participants recruited using remote, compared with face- 
to- face methods.
For the CARE75+ REMOTE pathway, we have devel-
oped a protocol that includes key outcomes and is not 
overly burdensome for self- completion or completion by 
telephone. However, we are aware that there are other 
important outcomes that would be pertinent to include. 
Therefore, we will monitor takeup and completion rates, 
alongside researcher feedback and consider the inclusion 
of further outcome measures. These could include, for 
example, loneliness or participation, or other measures 
considered a priority by academic partners and lay 
members.
The original CARE75+ methodology was previously 
very successful in recruiting older people from the South 
Asian population31 as a historically underserved popu-
lation.15 We will continue to include researchers with 
the appropriate community language skills to support 
recruitment of South Asian participants and will monitor 
take- up to see whether the previous success is maintained 
with the remote recruitment and assessment protocol. 
We aim to include people from different ethnocultural 
backgrounds where feasible to do so, mindful of language 
constraints.
We will provide regular participant newsletters, share 
results and host local events to facilitate continued 
engagement over the course of the study. We envisage this 
to be particularly important for a cohort that will other-
wise lack face- to- face contact with researchers.
The 2020 COVID- 19 pandemic has had a substantial 
impact on non- COVID- 19 research and has particularly 
impacted research, which requires face- to- face assess-
ment, and research involving older people.20 Many older 
people are considered vulnerable to COVID- 19 due to 
their age and due to health conditions prevalent within 
their age group. As such, face- to- face data collection 
techniques are likely to be affected by the pandemic for 
some time due to a combination of government imposed 
restrictions, due to COVID- 19, and older people them-
selves limiting unnecessary in- person interactions due to 
concerns about COVID- 19. The COVID- 19 pandemic has 
highlighted the need for timely, accessible information 
on the health and well- being of older populations. The 
remote model will support rapid, responsive data collec-
tion. CARE75+ REMOTE will contribute to a cohort with 
high strategic relevance, which will help shape UK and 
international research policy on ageing and frailty.
Author affiliations
1Academic Unit for Ageing and Stroke Research, Bradford Institute for Health 
Research, Bradford, UK
2Centre for Applied Dementia Studies, Faculty of Health Studies, University of 
Bradford, Bradford, UK
3College of Medicine and Health, University of Exeter, Exeter, UK
4School of Medicine, University of Keele, Keele, UK
5Academic Unit for Ageing and Stroke Research, University of Leeds, Faculty of 
Medicine and Health, Leeds, UK
6School of Healthcare, Faculty of Medicine and Health, University of Leeds, Leeds, 
UK
7School of Health and Related Research (ScHARR), The University of Sheffield, 
Sheffield, UK
8Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, 
UK
Twitter Victoria Goodwin @VickiG_physio, Karen Spilsbury @SpillersK and Andrew 
Clegg @CARE75study
Contributors LB: substantial contribution to the conception and design of the 
work; drafting the work and critical revisions; approval of final manuscript; 
accountable for all aspects of the work. AH: substantial contribution to the 
conception and design of the work; drafting the work and critical revisions; 
approval of final manuscript; accountable for all aspects of the work. CQ: 
substantial contribution to the conception and design of the work; drafting the 
work and critical revisions; approval of final manuscript; accountable for all 
aspects of the work. VG: substantial contribution to the conception and design of 
the work; drafting the work and critical revisions; approval of final manuscript; 
accountable for all aspects of the work. CC- G: substantial contribution to the 
conception and design of the work; drafting the work and critical revisions; 
approval of final manuscript; accountable for all aspects of the work. IJ: substantial 
contribution to the conception and design of the work; drafting the work and 
critical revisions; approval of final manuscript; accountable for all aspects of 
the work. FM: substantial contribution to the conception and design of the work; 
drafting the work and critical revisions; approval of final manuscript; accountable 
for all aspects of the work. SH: substantial contribution to the conception and 
design of the work; drafting the work and critical revisions; approval of final 
manuscript; accountable for all aspects of the work. CB: substantial contribution 
to the conception and design of the work; drafting the work and critical revisions; 
approval of final manuscript; accountable for all aspects of the work. VG: substantial 
contribution to the conception and design of the work; drafting the work and critical 
revisions; approval of final manuscript; accountable for all aspects of the work. KB: 
substantial contribution to the conception and design of the work; drafting the work 
and critical revisions; approval of final manuscript; accountable for all aspects of 
the work. AD- O: substantial contribution to the conception and design of the work; 
drafting the work and critical revisions; approval of final manuscript; accountable 
for all aspects of the work. KS: substantial contribution to the conception and 
design of the work; drafting the work and critical revisions; approval of final 
manuscript; accountable for all aspects of the work. BH: substantial contribution 
to the conception and design of the work; drafting the work and critical revisions; 
approval of final manuscript; accountable for all aspects of the work. TAY: 
substantial contribution to the conception and design of the work; drafting the work 
and critical revisions; approval of final manuscript; accountable for all aspects of 
the work. RH: substantial contribution to the conception and design of the work; 
drafting the work and critical revisions; approval of final manuscript; accountable 
for all aspects of the work. ET: substantial contribution to the conception and 
design of the work; drafting the work and critical revisions; approval of final 
manuscript; accountable for all aspects of the work. AC: substantial contribution to 
 on N
ovem









pen: first published as 10.1136/bm






10 Brown L, et al. BMJ Open 2021;11:e048524. doi:10.1136/bmjopen-2020-048524
Open access 
the conception and design of the work; acquisition of data for the work; drafting the 
work and critical revisions; approval of final manuscript; accountable for all aspects 
of the work.
Funding This research was funded by the NIHR Applied Research Collaboration 
(ARC) Yorkshire and Humber-https://www. arc- yh. nihr. ac. uk/ (study funding number 
NIHR200166), also supported by NIHR ARC South West Peninsula, ARC West 
Midlands and ARC North East and North Cumbria.
Disclaimer The views expressed in this publication are those of the author(s) and 
not necessarily those of the NHS, the National Institute for Health Research or the 
Department of Health and Social Care.
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting, or dissemination plans of this research. Refer to 
the Methods section for further details.
Patient consent for publication Not applicable.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Lesley Brown http:// orcid. org/ 0000- 0001- 5499- 9145
Victoria Goodwin http:// orcid. org/ 0000- 0003- 3860- 9607
Karen Spilsbury http:// orcid. org/ 0000- 0002- 6908- 0032
Barbara Hanratty http:// orcid. org/ 0000- 0002- 3122- 7190
Andrew Clegg http:// orcid. org/ 0000- 0001- 5972- 1097
REFERENCES
 1 Kinsella KG, Phillips DR. Global aging: the challenge of success, 
2005. Available: https://www. prb. org/ glob alag ingt hech alle ngeo fsuc 
cess pdf575kb/
 2 Kingston A, Robinson L, Booth H, et al. Projections of multi- 
morbidity in the older population in England to 2035: estimates from 
the population ageing and care simulation (PACSim) model. Age 
Ageing 2018;47:374–80.
 3 Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 
2013;381:752–62.
 4 O'Caoimh R, Sezgin D, O'Donovan MR, et al. Prevalence of frailty 
in 62 countries across the world: a systematic review and meta- 
analysis of population- level studies. Age Ageing 2021;50:96–104.
 5 Rockwood K, Song X, MacKnight C, et al. A global clinical measure 
of fitness and frailty in elderly people. CMAJ 2005;173:489–95.
 6 Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: 
evidence for a phenotype. J Gerontol A Biol Sci Med Sci 
2001;56:M146–57.
 7 Harrison JK, Clegg A, Conroy SP, et al. Managing frailty as a long- 
term condition. Age Ageing 2015;44:732–5.
 8 Clegg A, Relton C, Young J, et al. Improving recruitment of older 
people to clinical trials: use of the cohort multiple randomised 
controlled trial design. Age Ageing 2015;44:547–50.
 9 Heaven A, Brown L, Young J, et al. Community ageing research 75+ 
study (CARE75+): an experimental ageing and frailty research cohort. 
BMJ Open 2019;9:e026744.
 10 Brown L, Young J, Teale E. A cross- sectional study of the impact 
of pain in older people with frailty: findings from the community 
ageing research 75+ (CARE75+) study. Adv Geriatr Med Res 
2019;1:e190002.
 11 Nikolova S, Hulme C, West R, et al. Normative estimates and 
agreement between 2 measures of health- related quality of life 
in older people with frailty: findings from the community ageing 
research 75+ cohort. Value Health 2020;23:1056–62.
 12 Munyombwe T, West RM, Pendleton N. Mapping between the 
electronic frailty index and a research standard frailty index: findings 
from the community ageing research 75+ (care 75+) cohort study. 
Adv Geriatr Med Res 2020;2:e200023.
 13 Hale MD, Santorelli G, Brundle C, et al. A cross- sectional study 
assessing agreement between self- reported and general practice- 
recorded health conditions among community dwelling older adults. 
Age Ageing 2019;49:135–40.
 14 Coventry PA, McMillan D, Clegg A, et al. Frailty and depression 
predict instrumental activities of daily living in older adults: a 
population- based longitudinal study using the CARE75+ cohort. 
PLoS One 2020;15:e0243972.
 15 National Institute for Health Research. Improving inclusion of under- 
served groups in clinical research: guidance from the NIHR include 
project, 2020. Available: www. nihr. ac. uk/ documents/ improving- 
inclusion- of- under- served- groups- in- clinical- research- guidance- 
from- include- project/ 25435
 16 Farrow M, Biglands J, Tanner SF, et al. The effect of ageing on 
skeletal muscle as assessed by quantitative MR imaging: an 
association with frailty and muscle strength. Aging Clin Exp Res 
2021;33:291–301.
 17 Brown L, Mossabir R, Harrison N, et al. Life in lockdown: a telephone 
survey to investigate the impact of COVID- 19 lockdown measures on 
the lives of older people (≥75 years). Age Ageing 2021;50:341–6.
 18 National Institute for Health Research (NIHR) Applied Research 
Collaboration Yorkshire & Humber. Available: https://www. arc- yh. nihr. 
ac. uk/ [Accessed 28/10/2021].
 19 Heaven A, Brown L, Foster M, et al. Keeping it credible in cohort 
multiple randomised controlled trials: the community ageing research 
75+ (care 75+) study model of patient and public involvement and 
engagement. Res Involv Engagem 2016;2:30.
 20 Witham M, Gordon A, Henderson E. Pandemic research for older 
people: doing it better next time. Age Ageing 2021;50:276–278.
 21 Relton C, Torgerson D, O'Cathain A, et al. Rethinking pragmatic 
randomised controlled trials: introducing the "cohort multiple 
randomised controlled trial" design. BMJ 2010;340:c1066–967.
 22 Lincoln NB, Gladman JR. The extended activities of daily living scale: 
a further validation. Disabil Rehabil 1992;14:41–3.
 23 EuroQoL. EQ- 5D- 5L, 2020. Available: https:// euroqol. org/ eq- 5d- 
instruments/ eq- 5d- 5l- about/
 24 SF- 12v2™ Health Survey © 1992- 2002 by Health Assessment Lab, 
Medical Outcomes Trust and QualityMetric Incorporated. All rights 
reserved. SF- 12® is a registered trademark of Medical Outcomes 
Trust. (IQOLA SF- 12v2 Standard, English (United Kingdom) 8/02).
 25 Kroenke K, Strine TW, Spitzer RL, et al. The PHQ- 8 as a measure 
of current depression in the general population. J Affect Disord 
2009;114:163–73.
 26 Kroenke K, Spitzer RL, Williams JBW, et al. Anxiety disorders in 
primary care: prevalence, impairment, comorbidity, and detection. 
Ann Intern Med 2007;146:317–25.
 27 Wong A, Nyenhuis D, Black SE, et al. Montreal cognitive assessment 
5- minute protocol is a brief, valid, reliable, and feasible cognitive 
screen for telephone administration. Stroke 2015;46:1059–64.
 28 Clegg A, Bates C, Young J, et al. Development and validation of an 
electronic frailty index using routine primary care electronic health 
record data. Age Ageing 2016;45:353–60.
 29 Collerton J, Barrass K, Bond J, et al. The Newcastle 85+ study: 
biological, clinical and psychosocial factors associated with healthy 
ageing: study protocol. BMC Geriatr 2007;7:14.
 30 Medical Research Council. Maximising the value of UK population 
cohorts MRC strategic review of the largest UK population cohort 
studies, 2014. Available: https:// mrc. ukri. org/ publications/ browse/ 
maximising- the- value- of- uk- population- cohorts/ [Accessed 
28/10/2021].
 31 Jacob I, Mahmood F, Brown L, et al. Recruiting older people from 













pen: first published as 10.1136/bm
jopen-2020-048524 on 22 N
ovem
ber 2021. D
ow
nloaded from
 
